Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brincidofovir - Chimerix/Emergent Biosolutions

Drug Profile

Brincidofovir - Chimerix/Emergent Biosolutions

Alternative Names: BCV; BCV-001; Cidofovir hexadecyloxypropyl ester; Cidofovir PIM conjugate; CMX-001; CMX001-129; HDP-CDV; HDP-cidofovir; Hexadecyl-oxypropyl cidofovir - Chimerix; SyB-V-1901; TEMBEXA

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Brown University; Centers for Disease Control and Prevention; Chimerix; Emergent BioSolutions; National Cancer Centre (Singapore); National Institute of Neurological Disorders and Stroke; National Institutes of Health (USA); SymBio Pharmaceuticals; University of California at San Francisco; University of Oxford
  • Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Smallpox; Cytomegalovirus infections; Adenovirus infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Smallpox
  • Phase III Cytomegalovirus infections
  • Phase II/III Viral infections
  • Phase II Adenovirus infections; Human polyomavirus infections
  • Preclinical Epstein-Barr virus infections; Glioblastoma
  • No development reported Herpes simplex virus infections; Monkeypox
  • Discontinued Ebola virus infections

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for phase-I development in Viral-infections(In volunteers) in Japan (IV, Infusion)
  • 13 Dec 2023 Registered for Smallpox (In neonates, In infants, In children, In adults) in Canada (PO)
  • 09 Dec 2023 Effiacy and adverse events data from a phase II ATHENA trial in Adenovirus infection presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top